Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Withdrawn × 130-nm albumin-bound paclitaxel × Clear all

Phase

Phase 2 13 Phase 1/2 6 Phase 1 3 Phase EARLY_PHASE1 2 Phase 3 1

Status

Completed 24 Active not recruiting 22 Recruiting 18 Unknown 4 Terminated 4 Not yet recruiting 4 Withdrawn 1 Suspended 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 18 Carboplatin 12 Radiotherapy 11 Paclitaxel 10 Fluorouracil 9 Rituximab 7 Gemcitabine 7 Drug Therapy 6 Capecitabine 5 Bevacizumab 5 Vinorelbine 4 Nivolumab 4 Docetaxel 4 spartalizumab 3 pertuzumab 3 pembrolizumab 3 Trastuzumab 3 Standard of Care 3 Pemetrexed 3 Oxaliplatin 3 Methotrexate 3 Etoposide 3 Dexamethasone 3 Cyclophosphamide 3 Chemotherapy, Adjuvant 3 Cetuximab 3 Bendamustine Hydrochloride 3 tislelizumab 2 ribociclib 2 parsaclisib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05791097 2023-07-24

AdvanTIG-306

Novartis

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡